Consolidated Financial Results for the Second Quarter of Fiscal Year 2026 (IFRS)

November 13, 2026

Name of the listed company: **NIPPON SHINYAKU CO., LTD.** Listing stock exchange: Tokyo
Code No.: 4516 URL https://www.nippon-shinyaku.co.jp/
Representative: Toru Nakai, President and Representative Director
Contact: Kenji Ban, Department Manager and Finance & Accounting Dept. Tel. +81-75-321-9116
Scheduled date to file semi-annual securities report: November 16, 2026
Scheduled start of payment: December 4, 2026
Supplementary material: Yes
Financial result meeting: Yes (for institutional investors and securities analysts and the media)

* All amounts are rounded down to the nearest million yen.

1. Consolidated Financial Results for the Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)

(1) Operating results (¥ million)

	Revenue		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Comprehensive income	
Six months ended		%		%		%		%		%		%
September 30, 2026	97,830	22.8	19,272	(1.6)	20,006	(0.1)	15,474	(1.8)	15,472	(1.8)	3,015	(82.3)
Six months ended September 30, 2025	79,647	0.4	19,580	9.6	20,029	10.1	15,762	(3.8)	15,760	(3.7)	17,008	(9.9)

	Earnings per share (¥)	
	Basic	Diluted
Six months ended September 30, 2026	229.53	-
Six months ended September 30, 2025	233.88	233.88

Note: Equity-method investments: not applicable

(2) Financial position (¥ million)

	Total assets	Total equity	Total equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of September 30, 2026	335,890	290,747	290,426	86.5%
As of March 31, 2026	346,359	291,871	291,551	84.2%

2. Dividends

	Annual dividends per share (¥)				
	1st quarter	2nd quarter	3rd quarter	Year-end	Annual
Year ended March 31, 2026	—	62.00	—	62.00	124.00
Year ending March 31, 2027	—	62.00			
Year ending March 31, 2027 (forecast)			—	62.00	124.00

3. Business Forecast for the Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(¥ million)

	Revenue		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share (¥)
		%		%		%		%	
Full term	191,000	11.8	33,000	(7.0)	34,000	(6.8)	27,000	(9.2)	400.46

4. Others

(1) Changes in the scope of consolidation

Inclusion: None

Exclusion: None

(2) Changes in accounting policies and accounting estimates, and restatement

1. Changes in accounting policies arising from revision of accounting standards: None
2. Changes in accounting policies arising from other factors: None
3. Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

Number of shares outstanding (including treasury stock)

As of September 30, 2026:	70,251,484 shares
As of March 31, 2026:	70,251,484 shares

Number of shares of treasury stock

As of September 30, 2026:	2,828,235 shares
As of March 31, 2026:	2,850,555 shares

Average number of shares outstanding (total for the consolidated period)

As of September 30, 2026:	67,360,027 shares
As of September 30, 2025:	67,354,740 shares

Note:
This summary of semi-annual financial results is not subject to review procedures under the Financial Instruments and Exchange Act.

The above forecasts are based on data available as of the date of release of this document as well as assumptions based on uncertain factors, which might have a material effect on the Company’s performance in the future. Readers are advised that actual results may differ substantially from the above forecasts due to various unforeseeable factors.

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

5. Consolidated Financial Statement

(1) Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and cash equivalents	76,592	72,849
Trade and other receivables	46,157	48,462
Inventories	51,595	53,251
Other financial assets	2,414	2,750
Other current assets	6,326	6,769
Total current assets	183,086	184,083
Non-current assets		
Property, plant and equipment	34,954	35,705
Intangible assets	48,242	53,990
Right-of-use assets	2,588	3,336
Other financial assets	67,356	48,713
Deferred tax assets	6,957	6,957
Other non-current assets	3,172	3,102
Total non-current assets	163,272	151,806
Total assets	346,359	335,890

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	26,132	24,311
Other financial liabilities	273	302
Lease liabilities	913	1,406
Income taxes payable	6,979	4,257
Other current liabilities	7,806	8,169
Total current liabilities	42,105	38,447
Non-current liabilities		
Other financial liabilities	235	235
Lease liabilities	1,654	1,921
Retirement benefit liability	4,557	4,215
Deferred tax liabilities	5,875	265
Other non-current liabilities	59	57
Total non-current liabilities	12,382	6,695
Total liabilities	54,488	45,142
Equity		
Share capital	5,174	5,174
Capital surplus	4,547	4,568
Retained earnings	246,691	258,162
Treasury shares	(2,440)	(2,422)
Other components of equity	37,578	24,943
Total equity attributable to owners of parent	291,551	290,426
Non-controlling interests	319	321
Total equity	291,871	290,747
Total liabilities and equity	346,359	335,890

(2) Consolidated Statements of Income

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Revenue	79,647	97,830
Cost of sales	25,336	34,511
Gross profit	54,311	63,319
Selling, general and administrative expenses	20,357	22,763
Research and development expenses	14,637	20,679
Other income	521	835
Other expenses	258	1,439
Operating profit	19,580	19,272
Finance income	550	837
Finance costs	101	103
Profit before tax	20,029	20,006
Income tax expense	4,266	4,531
Profit	15,762	15,474
Profit attributable to		
Owners of parent	15,760	15,472
Non-controlling interests	2	1
Profit	15,762	15,474
Earnings per share		
Basic earnings per share	233.88	229.53
Diluted earnings per share	233.88	-

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit	15,762	15,474
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	1,272	(12,391)
Total of items that will not be reclassified to profit or loss	1,272	(12,391)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(27)	(68)
Total of items that may be reclassified to profit or loss	(27)	(68)
Total other comprehensive income	1,245	(12,459)
Comprehensive income	17,008	3,015
Comprehensive income attributable to		
Owners of parent	17,006	3,013
Non-controlling interests	2	1
Comprehensive income	17,008	3,015

(3) Consolidated Statements of Changes in Equity
Six months ended September 30, 2025

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance at beginning of period	5,174	4,491	222,640	(2,459)	(1,136)	18,318
Profit	-	-	15,760	-	-	-
Other comprehensive income	-	-	-	-	(27)	1,272
Comprehensive income	-	-	15,760	-	(27)	1,272
Purchase of treasury shares	-	-	-	(0)	-	-
Dividends of surplus	-	-	(4,177)	-	-	-
Share-based payment transactions	-	21	-	19	-	-
Transfer from other components of equity to retained earnings	-	-	1,985	-	-	(1,985)
Total transactions with owners	-	21	(2,192)	18	-	(1,985)
Balance at end of period	5,174	4,512	236,209	(2,440)	(1,163)	17,605

	Equity attributable to owners of parent		Non-controlling interests	Total
	Other components of equity	Total		
	Total			
Balance at beginning of period	17,181	247,028	312	247,340
Profit	-	15,760	2	15,762
Other comprehensive income	1,245	1,245	-	1,245
Comprehensive income	1,245	17,006	2	17,008
Purchase of treasury shares	-	(0)	-	(0)
Dividends of surplus	-	(4,177)	-	(4,177)
Share-based payment transactions	-	40	-	40
Transfer from other components of equity to retained earnings	(1,985)	-	-	-
Total transactions with owners	(1,985)	(4,137)	-	(4,137)
Balance at end of period	16,441	259,897	314	260,211

Six months ended September 30, 2026

(Millions of yen)

	Equity attributable to owners of parent					
					Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares	Exchange differences on translation of foreign operations	Financial assets measured at fair value through other comprehensive income
Balance at beginning of period	5,174	4,547	246,691	(2,440)	(587)	38,166
Profit	-	-	15,472	-	-	-
Other comprehensive income	-	-	-	-	(68)	(12,391)
Comprehensive income	-	-	15,472	-	(68)	(12,391)
Purchase of treasury shares	-	-	-	(0)	-	-
Dividends of surplus	-	-	(4,178)	-	-	-
Share-based payment transactions	-	21	-	19	-	-
Transfer from other components of equity to retained earnings	-	-	176	-	-	(176)
Total transactions with owners	-	21	(4,002)	18	-	(176)
Balance at end of period	5,174	4,568	258,162	(2,422)	(656)	25,599

	Equity attributable to owners of parent		Non-controlling interests	Total
	Other components of equity	Total		
	Total			
Balance at beginning of period	37,578	291,551	319	291,871
Profit	-	15,472	1	15,474
Other comprehensive income	(12,459)	(12,459)	-	(12,459)
Comprehensive income	(12,459)	3,013	1	3,015
Purchase of treasury shares	-	(0)	-	(0)
Dividends of surplus	-	(4,178)	-	(4,178)
Share-based payment transactions	-	40	-	40
Transfer from other components of equity to retained earnings	(176)	-	-	-
Total transactions with owners	(176)	(4,138)	-	(4,138)
Balance at end of period	24,943	290,426	321	290,747

(4) Consolidated Statements of Cash Flow

(Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before tax	20,029	20,006
Depreciation and amortization	3,233	3,630
Interest and dividend income	(550)	(837)
Interest expenses	49	52
Foreign exchange loss (gain)	(251)	621
Loss (gain) on sale and retirement of fixed assets	19	(292)
Decrease (increase) in trade and other receivables	(697)	(2,376)
Decrease (increase) in inventories	(5,128)	(1,678)
Increase (decrease) in trade and other payables	967	352
Increase (decrease) in retirement benefit liability	31	(341)
Other	634	191
Subtotal	18,338	19,327
Interest and dividends received	550	837
Interest paid	(49)	(52)
Income taxes paid	(4,897)	(7,193)
Net cash provided by (used in) operating activities	13,942	12,919
Cash flows from investing activities		
Payments into time deposits	(1,460)	(1,422)
Proceeds from withdrawal of time deposits	1,030	1,378
Purchase of property, plant and equipment	(1,678)	(1,934)
Proceeds from sale of property, plant and equipment	-	495
Purchase of intangible assets	(698)	(9,681)
Purchase of investments	(97)	(0)
Proceeds from sale and redemption of investments	3,645	266
Other	2	2
Net cash provided by (used in) investing activities	743	(10,896)
Cash flows from financing activities		
Repayments of lease liabilities	(720)	(839)
Purchase of treasury shares	(0)	(0)
Dividends paid	(4,173)	(4,177)
Net cash provided by (used in) financing activities	(4,894)	(5,017)
Effect of exchange rate changes on cash and cash equivalents	259	(748)
Net increase (decrease) in cash and cash equivalents	10,050	(3,742)
Cash and cash equivalents at beginning of period	55,241	76,592
Cash and cash equivalents at end of period	65,291	72,849

November 13, 2026
Unit: Millions of yen

Brand name	Indications	Q2 (April to September)			FY2026 Forecast
		FY2025	FY2026	Percentage change	Full-Year
Viltepso	Duchenne muscular dystrophy	10,349	11,352	9.7%	21,900
[Japan]		[2,386]	[2,513]	[5.3%]	[4,900]
[U.S.]		[7,963]	[8,839]	[11.0%]	[17,000]
Uptravi	Pulmonary arterial hypertension/ Chronic thromboembolic pulmonary hypertension	8,448	9,794	15.9%	19,700
Erleada	Prostate cancer	-	7,059	-	14,300
Vyxeos	High-risk acute myeloid leukemia	2,941	2,832	(3.7%)	6,200
Gazyva	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	2,451	2,717	10.8%	5,100
Fintepla	Seizures associated with Dravet syndrome/ Seizures associated with Lennox-Gastaut syndrome	1,765	2,707	53.3%	6,100
Defitelio	Sinusoidal obstruction syndrome	1,252	1,237	(1.2%)	2,500
Cialis	Erectile dysfunction	1,119	999	(10.7%)	2,000
Deramiocel (U.S.)	Duchenne muscular dystrophy	-	-	-	-
Profit in co-promotion		4,792	4,354	(9.1%)	8,600
Revenues from the licensing of industrial property rights		24,181	28,267	16.9%	54,000
Viltepso (export)		30	3,147	10379.6%	4,500
Pharmaceuticals		68,561	85,512	24.7%	166,500
Functional Food		11,086	12,318	11.1%	24,500
Revenue		79,647	97,830	22.8%	191,000

(Revenue based on the NHI drug price)

Jaypirca※	Mantle cell lymphoma Chronic lymphocytic leukemia	1,086	2,209	103.2%	-

※Sales forecasts for Jaypirca are not disclosed.

Nippon Shinyaku：R&D Pipeline List

November 13, 2026

Stage	Code No. (Generic name)	Therapeutic field	Indications	Origin	Development	Target area for application
Launch Additional Phase III study under consideration	NS-065/NCNP-01 (viltolarsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase III extension study	CAP-1002 (deramiocel)	intractable and rare diseases	Duchenne muscular dystrophy	Partnered with Capricor Therapeutics, Inc.	Capricor Therapeutics, Inc.	U.S.
Filed	GA101 (obinutuzumab)	intractable and rare diseases	Idiopathic nephrotic syndrome	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
Filed	MT-2111 (loncastuximab tesirine)	hematologic malignancies	Relapsed or refractory diffuse large B-cell lymphoma	ADC Therapeutics SA	Tanabe Pharma Corporation	Japan
Preparation for BLA	Tadekinig alfa	intractable and rare diseases	NLRC4 and XIAP mutations	AB2 Bio Ltd.	AB2 Bio Ltd.	U.S.
Preparation for BLA	RGX-121 (clemidsogene lanparvovec)	intractable and rare diseases	Mucopolysaccharidosis Type II	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Phase III	ZX008 (fenfluramine hydrochloride)	intractable and rare diseases	CDKL5 deficiency disorder	Distribution partnership with UCB S.A. (formerly known as Zogenix, Inc.)	UCB S.A. (formerly known as Zogenix, Inc.)	Japan
			Rett syndrome			
Phase III	GA101 (obinutuzumab)	intractable and rare diseases	Lupus nephritis	In-licensed from Chugai Pharmaceutical Co., Ltd.	Co-development with Chugai Pharmaceutical Co., Ltd.	Japan
			Extra renal lupus			
Phase III	LY3527727 (pirtobrutinib)	hematologic malignancies	Mantle cell lymphoma	Alliance agreement in Japan with Eli Lilly Japan K.K.	Eli Lilly Japan K.K.	Japan
			Chronic lymphocytic leukemia			
Phase III	NS-304 (selexipag)	cardiovascular	Arteriosclerosis obliterans	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
Phase II	NS-580 (friluglanstat)	gynecological diseases	Endometriosis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
		urological diseases	Chronic prostatitis / Chronic pelvic pain syndrome			
Phase II	NS-089/NCNP-02 (brogidirsen)	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase II	NS-229	intractable and rare diseases	Eosinophilic granulomatosis with polyangiitis	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase II	NS-035	intractable and rare diseases	Fukuyama congenital muscular dystrophy	Co-development with Kobe University	Nippon Shinyaku Co., Ltd.	Japan
Preparation for Phase II	NS-863	cardiovascular	Pulmonary arterial hypertension	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan/U.S.
			Pulmonary hypertension associated with interstitial lung disease			
Preparation for Phase II	NS-025	urological diseases	Urological diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan
		autoimmune disease	Xerostomia (dry mouth) associated with Sjögren's disease		Aquelys Therapeutics, Inc.	Japan/U.S.
Phase I/II	NS-050/NCNP-03	intractable and rare diseases	Duchenne muscular dystrophy	Co-development with National Center of Neurology and Psychiatry	Nippon Shinyaku Co., Ltd.	Japan/U.S.
Phase I/II	ATSN-101	intractable and rare diseases	GUCY2D-associated Leber congenital amaurosis	In-licensed from Atsena Therapeutics, Inc.	Atsena Therapeutics, Inc.	U.S.
Phase I/II	RGX-111	intractable and rare diseases	Mucopolysaccharidosis Type I	Partnered with REGENXBIO Inc.	REGENXBIO Inc.	U.S.
Phase I	NS-917 (radgocitabine)	hematologic malignancies	Relapsed/refractory acute myeloid leukemia	In-licensed from Delta-Fly Pharma, Inc.	Nippon Shinyaku Co., Ltd.	Japan
Phase I	NS-245	inflammatory diseases	Inflammatory diseases	Nippon Shinyaku Co., Ltd.	Nippon Shinyaku Co., Ltd.	Japan